Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai’s Cardio Suite at AHA 2026
Business Wire•06/11/2026•09:12 ET
2
Key Highlights
- ➤Viz HCM abstracts accepted for presentation at AHA 2026’s HCMS meeting
- ➤University of Colorado study analyzed ECGs from more than 29,000 patients
- ➤Nearly 40% of Viz HCM-flagged patients lacked corresponding diagnosis codes
- ➤Beth Israel study found flagged patients faced a 2.68-fold higher adverse-event hazard
- ➤Viz HCM developed under a multi-year Viz.ai–Bristol Myers Squibb agreement
Expert Statements
Jordan B. Strom, MD, MSc, Beth Israel Deaconess Medical Center
“We've been using ECGs for decades, but we're still discovering just how much they can tell us”
Jordan B. Strom, MD, MSc, Beth Israel Deaconess Medical Center
“In our study, Viz HCM added meaningful information beyond standard ECG interpretation in identifying patients with suspected disease. This opens up exciting possibilities for how we use a test we already rely on every day to better evaluate and care for patients.”
Tim Showalter, MD, Chief Medical Officer at Viz.ai
“Most patients with HCM are never diagnosed, and the ones who are often wait years. What these two studies show is that the ECGs that health systems are already collecting contain the signal to change that”
Tim Showalter, MD, Chief Medical Officer at Viz.ai
“Collaborations like these are essential to advancing our understanding of what’s possible with the technology within the Viz Cardio Suite and bringing these innovations into everyday clinical care, where they can make a meaningful difference for patients.”
Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai’s Cardio Suite at AHA 2026
Studies from Beth Israel Deaconess and the University of Colorado highlight how AI-ECG can help clinicians identify suspected cardiac disease from routine ECGs
Get started
Create a free account to read the full story.